Skip Navigation

Cardiovascular Research 2002 54(2):456-461; doi:10.1016/S0008-6363(02)00243-2
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shi, Y.
Right arrow Articles by Nattel, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, Y.
Right arrow Articles by Nattel, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure

Yanfen Shi, Danshi Li, Jean-Claude Tardif* and Stanley Nattel

Montreal Heart Institute, Research Center and Department of Medicine, 5000 Belanger Street East, Montreal, HlT 1C8 Quebec, Canada

* Corresponding author. Tel.: +1-514-376-3330x3564; fax: +1-514-593-2500 tardifjc{at}icm.umontreal.ca

Objective: Atrial remodeling contributes to the maintenance of atrial fibrillation (AF) in several cardiac disorders. There is evidence that angiotensin-converting enzyme (ACE) inhibitors reduce the prevalence of AF in patients with congestive heart failure (CHF). There have been no studies performed to assess the effects of ACE inhibitors on atrial dimensions and emptying function in relationship to vulnerability to AF in the setting of experimental CHF. Methods: CHF was produced in 20 dogs by rapid right ventricular pacing during 5 weeks. The dogs were randomized to enalapril (EN) therapy (2 mg/kg/day, n=10) or to a control group (n=10). Echocardiography was performed at baseline and weekly thereafter. At the 5-week electrophysiological study, AF was induced by burst pacing and AF duration was measured. Results: Atrial areas increased significantly with CHF. Left atrial (LA) fractional area shortening (FAS) decreased by 42% (P=0.0001) in controls but by 9% (P=NS) in the EN group (P=0.01, EN vs. controls). Similar findings were observed for right atrial (RA) changes (P=0.02). Atrial fibrosis was highly correlated with the decrease in LA FAS (r=0.85, P<0.01) and was reduced by EN (from 11.2±1.6 to 8.3±0.7%, P=0.008). AF duration was 720±461 s for controls and 138±83 s for EN (P=0.001). LA and RA areas and FAS at 5 weeks correlated with AF duration (P≤0.001 for all). FAS decrease in both atria also correlated with AF duration at follow-up (r=0.78 and 0.77 for LA and RA, P≤0.001 for both). Conclusions: Experimental CHF causes structural and functional abnormalities in both atria, which are correlated with AF duration. ACE inhibition attenuates CHF-induced atrial fibrosis and remodeling and reduces associated AF promotion. These results indicate a role for the renin–angiotensin system in arrhythmogenic atrial structural remodeling in CHF.

KEYWORDS ACE inhibitors; Arrhythmia (mechanisms); Atrial function; Fibrosis; Heart failure; Remodeling; Supraventr. arrhythmia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
The GISSI-AF Investigators
Valsartan for Prevention of Recurrent Atrial Fibrillation
N. Engl. J. Med., April 16, 2009; 360(16): 1606 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
A. D. Leonard, J. P. Thompson, E. L. Hutchinson, S. P. Young, J. McDonald, J. Swanevelder, and D. G. Lambert
Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease
Br. J. Anaesth., April 1, 2009; 102(4): 477 - 484.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
A. Bollmann, A. Tveit, D. Husser, M. Stridh, L. Sornmo, P. Smith, and S. B. Olsson
Fibrillatory rate response to candesartan in persistent atrial fibrillation
Europace, October 1, 2008; 10(10): 1138 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
D. Rusinaru, L. Leborgne, M. Peltier, and C. Tribouilloy
Effect of atrial fibrillation on long-term survival in patients hospitalised for heart failure with preserved ejection fraction
Eur J Heart Fail, June 1, 2008; 10(6): 566 - 572.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.